Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American ...

CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, complements CNSide Diagnostics' ...

・Plus has appointed Eric J. Daniels as its chief development officer, effective April 20. ・The company also received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma ...

) has been revised to $38.76 / share. This is a decrease of 72.34% from the prior estimate of $140.15 dated April 12, 2026. The price target is an average of many targets provided by analysts. The ...

We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Plus Therapeutics Inc. (NASDAQ:PSTV) stands against other ...

Plus Therapeutics Inc. Annual stock financials by MarketWatch. View the latest PSTV financial statements, income statements and financial ratios.

Plus Therapeutics Inc (NASDAQ:PSTV) shares are trading higher by 244% to $1.75 during Thursday’s session after the company announced that the FDA accepted the name REYOBIQ for the company’s lead asset ...